LILLY Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and when can generic versions of LILLY drugs launch?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.
Summary for LILLY
| International Patents: | 30 |
| US Patents: | 1 |
| Tradenames: | 85 |
| Ingredients: | 81 |
| NDAs: | 105 |
Drugs and US Patents for LILLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | CORDRAN N | flurandrenolide; neomycin sulfate | CREAM;TOPICAL | 050346-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | V-CILLIN K | penicillin v potassium | TABLET;ORAL | 060003-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | ONCOVIN | vincristine sulfate | INJECTABLE;INJECTION | 014103-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | AMPICILLIN SODIUM | ampicillin sodium | INJECTABLE;INJECTION | 062565-001 | Apr 4, 1985 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | SULFONAMIDES DUPLEX | sulfadiazine; sulfamerazine | SUSPENSION;ORAL | 006317-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | DELTALIN | ergocalciferol | CAPSULE;ORAL | 080884-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | BETALIN 12 | cyanocobalamin | INJECTABLE;INJECTION | 080855-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LILLY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | FORTEO | teriparatide | SOLUTION;SUBCUTANEOUS | 021318-001 | Nov 26, 2002 | 7,163,684 | ⤷ Subscribe |
| Lilly | PROZAC | fluoxetine hydrochloride | TABLET;ORAL | 020974-001 | Mar 9, 1999 | 4,626,549*PED | ⤷ Subscribe |
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-004 | Jan 7, 2008 | 7,182,958*PED | ⤷ Subscribe |
| Lilly | PROZAC | fluoxetine hydrochloride | SOLUTION;ORAL | 020101-001 | Apr 24, 1991 | 4,626,549*PED | ⤷ Subscribe |
| Lilly | FORTEO | teriparatide | SOLUTION;SUBCUTANEOUS | 021318-002 | Jun 25, 2008 | 7,144,861 | ⤷ Subscribe |
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,811,120 | ⤷ Subscribe |
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-003 | Nov 21, 2003 | 6,943,166*PED | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
| ➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
| ➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
| ➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
| ➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
| ➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
| ➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
| ➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
| ➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
International Patents for LILLY Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 336161 | ⤷ Subscribe |
| Denmark | 1732629 | ⤷ Subscribe |
| South Africa | 200606885 | ⤷ Subscribe |
| Montenegro | 03411 | ⤷ Subscribe |
| South Korea | 20060131946 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2005097233 | ⤷ Subscribe |
| Denmark | 1732628 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LILLY Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1539166 | 13C0062 | France | ⤷ Subscribe | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
| 2101777 | 93081 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
| 1280520 | C300722 | Netherlands | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 |
| 1280520 | 300722 | Netherlands | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 |
| 0432677 | SPC/GB05/011 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920 |
| 0273658 | 2005C/001 | Belgium | ⤷ Subscribe | PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811 |
| 2101777 | 300813 | Netherlands | ⤷ Subscribe | PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
